Ladenburg Thalmann Downgrades Noven Pharmaceuticals (NOVN) to Neutral
NOVN Hot Sheet
Rating Summary:0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Ladenburg Thalmann downgrades Noven Pharmaceuticals (Nasdaq: NOVN) from Buy to Neutral.
To see more analyst ratings on NOVN Click Here.
Noven Pharmaceuticals, Inc. engages in the research, development, manufacture, licensing, marketing, and sale of prescription pharmaceutical products.
To see more analyst ratings on NOVN Click Here.
Noven Pharmaceuticals, Inc. engages in the research, development, manufacture, licensing, marketing, and sale of prescription pharmaceutical products.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Brean Murray Carret & Co. Downgrades NetApp (NTAP) to Hold; Visibility Challenged
- Barclays on U.S. REITs: Best Ideas List: Adding HPP; Removing ARE
Create E-mail Alert Related Categories
DowngradesRelated Entities
Ladenburg Thalmann Financial ServicesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
